Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 302Magnetic Resonance Spectroscopy 261pembrolizumab 249Carboplatin 184Cyclophosphamide 175Biopsy 167Cisplatin 157Gemcitabine 134Paclitaxel 130Bevacizumab 123fludarabine 115Nivolumab 108Radiotherapy 107Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 78Dexamethasone 76Pemetrexed 72Rituximab 69Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 64Doxorubicin 63Standard of Care 62Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Serotonin 5-HT3 Receptor Antagonists × 90 days × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡